Dotinurad｜Hyperuricemia｜HongKong DengYue Medicine

Dotinurad Application Scope

Dotinurad is a selective urate reabsorption inhibitor used for the treatment of hyperuricemia and gout.

It works by inhibiting the urate transporter URAT1 in the kidneys, promoting uric acid excretion and lowering serum uric acid levels.

Dotinurad Characteristics

Ingredients:

• Active ingredient: Dotinurad
• Inactive ingredients: May include excipients such as lactose, microcrystalline cellulose, and magnesium stearate (specific formulation depends on the manufacturer).

Properties:

• White to off-white powder or granules.
• Soluble in water and organic solvents.

Specification:

• Available in tablet form, typically in doses of 0.5 mg, 1 mg, or 2 mg.

Packaging Specification:

• Blister packs or bottles containing 30, 60, or 100 tablets.

Storage:

• Store at room temperature (15–30°C) in a dry place, protected from light and moisture.

Expiry Date:

• Typically 24–36 months from the date of manufacture (check the packaging for the exact date).

Executive Standard:

• Complies with pharmacopeial standards (e.g., JP: Japanese Pharmacopoeia).

Approval Number:

• Varies by region (e.g., Japan: NDA approval number provided by the PMDA).

Date of Revision:

• Check the latest package insert or manufacturer’s documentation for the most recent revision date.

Manufacturer:

• Fuji Yakuhin Co., Ltd. (Japan) or other licensed manufacturers.

Guidelines For The Use Of Dotinurad

Dosage and Administration:

• Adults: The usual dose is 0.5–2 mg once daily, taken orally with or without food.
• Dosage should be adjusted based on serum uric acid levels and patient response.
• Always follow the prescribing physician’s instructions.

Dotinurad Side Effects:

• Common: Headache, dizziness, gastrointestinal discomfort (e.g., nausea, diarrhea).
• Rare: Hypersensitivity reactions, liver function abnormalities, renal impairment.

Contraindications:

• Hypersensitivity to Dotinurad or any of its components.
• Severe renal impairment or end-stage renal disease.
• Pregnancy and breastfeeding (unless explicitly advised by a healthcare provider).

Precautions:

• Monitor renal function and serum uric acid levels regularly.
• Use with caution in patients with a history of kidney stones or hepatic impairment.
• Avoid concomitant use with other uric acid-lowering agents unless directed by a physician.

Dotinurad Interactions

Drug Interactions:

• Xanthine Oxidase Inhibitors (e.g., Allopurinol, Febuxostat): May enhance uric acid-lowering effects; monitor serum uric acid levels.
• Diuretics (e.g., Thiazides, Loop Diuretics): May reduce the efficacy of Dotinurad.
• NSAIDs (e.g., Ibuprofen, Aspirin): May increase the risk of renal impairment.
• Probenecid: May interfere with uric acid excretion; avoid concomitant use.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.